Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
14.04. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
27.02. | C4 Therapeutics GAAP EPS of -$0.49 beats by $0.02, revenue of $5.2M beats by $0.77M | 4 | Seeking Alpha | ||
27.02. | C4 Therapeutics, Inc.: C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | 237 | GlobeNewswire (Europe) | Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma; Trials Expected to Initiate in Early 2026 CFT1946 Phase 1/2 Trial... ► Artikel lesen | |
27.02. | C4 Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
27.02. | C4 Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
27.02. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
14.01. | C4 Therapeutics gains after portfolio updates | 2 | Seeking Alpha | ||
14.01. | C4 Therapeutics macht Fortschritte bei wichtigen klinischen Studien für 2025 | 4 | Investing.com Deutsch | ||
14.01. | C4 Therapeutics, Inc.: C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology | 160 | GlobeNewswire (Europe) | Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin's... ► Artikel lesen | |
14.01. | C4 Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
09.12.24 | Aktien von C4 Therapeutics steigen nach positiven frühen Krebsstudienergebnissen | 6 | Investing.com Deutsch | ||
09.12.24 | C4 Therapeutics stock surges on positive early cancer trial results | 2 | Investing.com | ||
09.12.24 | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
08.12.24 | C4 Therapeutics, Inc.: C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader | 152 | GlobeNewswire (Europe) | In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR)... ► Artikel lesen | |
20.11.24 | C4 Therapeutics beruft Steve Hoerter in den Vorstand | 2 | Investing.com Deutsch | ||
20.11.24 | C4 Therapeutics appoints Steve Hoerter to board | 1 | Investing.com | ||
20.11.24 | C4 Therapeutics, Inc.: C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors | 1 | GlobeNewswire (USA) | ||
20.11.24 | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
31.10.24 | C4 Therapeutics GAAP EPS of -$0.35 beats by $0.05, revenue of $15.36M beats by $10.76M | 4 | Seeking Alpha | ||
31.10.24 | C4 Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
COHERUS | 0,963 | -2,98 % | Coherus loses commercial chief amid exit from biosimilar space | ||
CUE BIOPHARMA | 0,685 | 0,00 % | Cue Biopharma stock holds $2 target, Market Outperform rating | ||
SOLID BIOSCIENCES | 3,540 | -0,42 % | Solid Biosciences Inc.: Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates | - Duchenne: Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration... ► Artikel lesen | |
EVOTEC | 7,326 | +1,50 % | DAX stabil, Gold stark: EZB-Zinsentscheid, Siemens Energy, Sartorius, Evotec, TSMC, Netflix ... | Der DAX hat sich am Mittwoch im Tagesverlauf stabilisieren können. Aus dem Handel ging er mit einem Minus von 0,5 Prozent auf 21.151 Zähler. Auch zum Start in den Donnerstag wird der deutsche Leitindex... ► Artikel lesen | |
TEMPUS AI | 51,04 | +2,97 % | Gemeinsam gegen Krebs: Tempus AI, AstraZeneca und Pathos AI entwickeln KI-Modell | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat heute bekannt gegeben, zusammen mit AstraZeneca und Pathos AI ein Foundation-Modell im Bereich der Onkologie zu entwickeln.... ► Artikel lesen | |
QIAGEN | 37,500 | -0,12 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für Qiagen bei einem Kursziel von 48 US-Dollar auf "Neutral" belassen. Die Ziele seien bestätigt worden, nähere Details seien... ► Artikel lesen | |
BIONTECH | 102,60 | +1,18 % | BioNTech-Aktie: Ein schnelles Ende! | News von Trading-Treff.de BioNTech schafft es derzeit einfach nicht, die negativen Stimmungen am Markt zu besiegen. Die Aktie verlor am Donnerstag rund 1,6 %. Damit ist der Wert wieder auf dem Weg in... ► Artikel lesen | |
MINERALYS THERAPEUTICS | 13,530 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM) | ||
TARSUS PHARMACEUTICALS | 49,990 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 ... | ||
NURIX THERAPEUTICS | 11,640 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions | Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical... ► Artikel lesen | |
CG ONCOLOGY | 20,720 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates | - Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated... ► Artikel lesen | |
ADMA BIOLOGICS | 22,200 | +2,07 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
BICARA THERAPEUTICS | 15,480 | 0,00 % | Bicara wird aktualisierte Studiendaten auf ASCO-Tagung präsentieren | ||
HARMONY BIOSCIENCES | 28,910 | 0,00 % | JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? | ||
RECURSION PHARMACEUTICALS | 5,660 | +1,62 % | Recursion Pharmaceuticals: Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025 |